Navigation Links
NeoGenomics to Present at the Roth Capital Partner's 21st Annual OC Growth Stock Conference
Date:2/11/2009

FT. MYERS, Fla., Feb. 11 /PRNewswire-FirstCall/ -- NeoGenomics, Inc. (OTC Bulletin Board: NGNM), a leading provider of cancer genetics testing services, announced today that President and Chief Scientific Officer, Bob Gasparini, will present at the Roth Capital Partner's 21st Annual OC Growth Stock Conference in Dana Point, California. The date, time and location of the Company's presentation at the conference are as follows:

        Date:          Monday, February 16, 2009
        Time:          4:20 PM Pacific Time
        Venue:         The Ritz Carlton Laguna Niguel
                       One Ritz-Carlton Drive
                       Dana Point, California 92629

Webcast Link: http://www.wsw.com/webcast/roth20/ngnm/

The Roth 21st Annual OC Growth Stock Conference will feature presentations from over 200 growth companies. This event is designed to provide investors with a unique opportunity to gain insight into leading companies across all sectors. Additionally, there will be a special track dedicated to microcap companies. A live audio webcast of the presentation can be accessed at http://www.wsw.com/webcast/roth20/ngnm/. A PowerPoint presentation and a link to the webcast can also be accessed through the investor relations section of the NeoGenomics website at http://www.neogenomics.org at the time of the conference. The webcast will be available for three months. Interested parties and investors may also find more information about the conference by contacting conference@roth.com or calling (800) 933-6830.

About NeoGenomics, Inc.

NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, and hospitals throughout the United States. For additional information about NeoGenomics, visit http://www.neogenomics.org.

Interested parties can also access additional investor relations material from the American Microcap Institute at http://www.americanmicrocapinstitute.com/ngnm/ or from Hawk Associates at http://www.hawkassociates.com. An investment profile about NeoGenomics may be found at www.hawkassociates.com/profile/ngnm.cfm .

About Roth

Roth is a full service investment banking firm dedicated to the small and micro-cap market. Since the inception of the firm in 1984, Roth has been a leader and innovator in the small and micro cap markets. Roth's exclusive focus has been, is, and will continue to offer a full spectrum of investment banking services, including raising capital, research coverage, trading and market making, merger and acquisition advisory services, and investor conferences.


'/>"/>
SOURCE NeoGenomics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. NeoGenomics Schedules Its Q3 2008 Earnings Release for November 6, 2008
2. NeoGenomics to Present at the Noble Financial Equity Conference
3. NeoGenomics Announces Results for the Second Quarter of Fiscal Year 2008
4. NeoGenomics Announces Results for the 3rd Quarter 2007
5. NeoGenomics, Inc. Schedules its Q3 07 Earnings Conference Call For Wednesday, November 14, 2007 at 11:00 AM
6. Hill-Rom to Present at the Canaccord Adams Musculoskeletal Conference
7. Penn Medicine presents HIV gene therapy trial data at CROI 2009
8. NuVasive to Present at ROTH 21st Annual OC Growth Stock Conference
9. VNUS Medical Technologies to Present at the Roth 21st Annual OC Growth Stock Conference
10. Prism Pharmaceuticals Study of Injectable Clopidogrel Accepted for Presentation at the American College of Cardiology
11. Covance to Present at the 2009 UBS Global Healthcare Services Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... Medforce Technologies, Inc., ... to announce it has joined the National Association for Home Care and Hospice ... ill, disabled, and dying Americans of all ages and the caregiver who provide ...
(Date:3/28/2017)... ... March 28, 2017 , ... Alert Sentry Group LLC., ... (Mobile Personal Emergency Response Systems), the iSAFE and the iSAFE Plus. These iSAFE products ... first of their kind, the iSAFE and iSAFE Plus offer direct GPS Location and ...
(Date:3/28/2017)... ... March 28, 2017 , ... Usually, the impending arrival ... wardrobe. However, for those self-conscious about a double chin, this means more anxiety than ... solution. , “For most people, a double chin is undesirable,” Dr. Goldman said, ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... leading physicians, Paul Yost, will begin serving as new board chair for Orange ... month. Yost will serve the remainder of soon-to-be former chair Mark Refowitz’s term, ...
(Date:3/28/2017)... ... , ... With less than 10,000 dermatologists in the United States and more ... while the desire to conquer breakouts and eliminate skincare stress is widespread. Curology ... today released its inaugural survey on the State of Acne in America. , ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... , March 28, 2017 The ... reach USD 8.0 billion by 2025, according to a ... incidence of infectious diseases and cancer is expected to ... disease diagnosis over the coming years. In addition, higher ... autologous and allogenic stem cell therapy, due to adverse ...
(Date:3/27/2017)... 27, 2017 Summary This ... Bayer and its partnering interests and activities since 2010. ... an in-depth insight into the partnering activity of one of ... company reports are prepared upon purchase to ensure inclusion of ... The report will be delivered in PDF format within ...
(Date:3/27/2017)... , March 27, 2017  ImMAGE Biotherapeutics (OTCMKTS: IMMG), ... successfully passed early toxicology and efficacy studies. The company ... target a specific protein, MAGE A, in an effort ... cancer. After 4 weeks of treatment ... show very little toxicity in a full toxicology report ...
Breaking Medicine Technology: